fashion -WSS

fashion

author：focus 2025-09-27 09:44:58 - browse：817

JOSEPH PREZIOSO/AFP via Getty Images

Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that the drug was both safe and offered modest pain relief. But the findings also prompted fresh debate on Tuesday about how widely used the therapy would be should it win regulatory approval.

The company reported that its small molecule drug, VX-548, outperformed placebo in a pair of pain relief trials that recruited patients who had gotten an abdominoplasty (tummy tuck) or bunion surgery. The study also found that the drug was generally safe, with fewer patients on the medication reporting adverse events than those who had taken a placebo. But there was a catch: VX-548 didn’t outperform a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint. And in the bunionectomy study, the opioid comparator beat VX-548 on pain relief.

“While this study was not explicitly designed to test VX-548 vs. the opioid comparator, this may complicate the prescribing decision in the acute setting, where patients often take a short course of treatment and efficacy is a primary consideration,” Stifel market analyst Paul Matteis wrote in a note to investors, adding that results from three Phase 3 studies were positive overall.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Information blocking fines are now fair game in health care

explore

WSS

David Liu startup to focus on CRISPR delivery

Grad students accuse University of California of wage theft

Flu vaccine offering decent levels of protection this winter, new data show

House looks to weaken Medicare negotiation

International team creates first chimeric human

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

hotspot

fashion

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

How to address the problem of discarded donor organs

Medical records are filled with copy

Assistant physicians can help address the primary care shortage

Hepatitis C has a cure — but many Americans still lack access to it

ALS groups 'won't be played again' by the FDA, drug sponsors

United colonoscopy coverage change 'may cost lives,' doctors say

Kenai launches with $82 million for Parkinson’s stem cell therapy

Moonlake's readout produced a cash windfall. Risks remain

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

focus

Why getting cancer drugs just got harder for rural patients

What happened to the House vote on health price transparency?

White House Covid adviser calls on docs to combat misinformation

How to address the problem of discarded donor organs

RaDonda Vaught to speak at CommonSpirit event on patient safety

Medicare to pay more for cardiac rehab in hospital outpatient clinics

focus

explore

explore

knowledge